Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers-Reference-Cited by-同舟云学术

Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers

Published:2024-02-23 Issue:4 Volume:63 Page:469-481
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Rohr Brit S.,Krohmer Evelyn^ORCID,Foerster Kathrin I.^ORCID,Burhenne Jürgen^ORCID,Schulz Martin^ORCID,Blank Antje^ORCID,Mikus Gerd^ORCID,Haefeli Walter E.^ORCID

Funder

Medizinischen Fakultät Heidelberg, Universität Heidelberg

Universitätsklinikum Heidelberg

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40262-024-01350-x.pdf

Reference66 articles.

1. Lamb YN. Nirmatrelvir plus ritonavir: first approval. Drugs. 2022;82(5):585–91. https://doi.org/10.1007/s40265-022-01692-5.

2. Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G. Concentration effect relationship of CYP3A inhibition by ritonavir in humans. Eur J Clin Pharmacol. 2013;69(10):1795–800. https://doi.org/10.1007/s00228-013-1530-8.

3. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):4–9. https://doi.org/10.1093/jac/dkh029.

4. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008;42(7):1048–59. https://doi.org/10.1345/aph.1K615.

5. Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2010;31(1):22–35. https://doi.org/10.1016/j.tips.2009.10.001.